Pharma

Molecule, a decentralized biopharma marketplace, has developed a novel IP-to-NFT framework with Web3 technology innovator Nevermind. In a historic transaction, the first biopharma IPNFT was successfully transferred to research collective VitaDAO to fund novel longevity therapeutics at the University of Copenhagen. (1) https://www.molecule.to/ A marketplace for biotech intellectual property and…

Executive Summary Endosane is a new take on developing drugs. Endosane is a joint venture of a group of researchers (Prof. Leweke and Dr. Rohleder) and the Sanity Group. Their goal is to apply cannabinoid compounds to develop drugs for neurologic and psychiatric applications. Our background is in neurology and psychiatry ……

So how Decentralized Science will impact Pharma? The movement applies decentralized ideas and technology to improve and advance modern science. The movement itself is on its infancy, there is no ‘De-Sci Club’ or Association with a members rules books, manifesto or roadmap describing what it exactly wants to achieve. We…

The pandemic has made it necessary for pharma companies to deal with clients on a special basis. The pharma industry has indeed faced a lot of pressure due to the pandemic over the years. Because of the coronavirus, the role of the medical sales staff became quite challenging because the…

A version of this article was previously published in the Journal of mHealth. With our growing dependence on social media over the past decade, Digital Opinion Leaders–or “DOLs” for short–are becoming an increasingly important stakeholder group for Pharma teams to engage and consult. …

Decentralized science (DeSci) is a fairly new movement that is having a noticeable impact on how science is conducted today, and many speculate it will have even a bigger impact in the near future. This piece will try to explain Decentralized science in simple terms: What is it? Who is…

According to IQVIA, which has published reports on launch excellence in prescription medicines since 2007, only 4% of primary care and 6% of specialty launches are excellent. We define launch excellence in the life science industry as a steep and sustained launch uptake curve, superior promotional performance, significant market share…

In April, the New York Times endorsed historic reforms to the U.S. patent system. For those of us advocating for a more just and equitable medicines system, this was clearly a watershed moment. After all, there’s no fixing the drug pricing problem without fixing the drug patent problem. Every time…